Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17805
Corporate User License Price USD 750
Corporate User License Price INR 53415
Site License Price USD 500
Site License Price INR 35610
Request a Quote

Report Title

RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology to develop product candidates. The company offers products for the treatment of metabolic, muscle, hematologic, ocular and neurodegenerative diseases and disorders. Its products also find application in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc (RGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

RegenxBio Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

REGENXBIO Raises USD70.5 Million in Series D Financing 13

REGENXBIO Raises USD30 Million in Series C Financing 16

REGENXBIO Raises USD7.9 Million in Venture Financing 18

ReGenX Biosciences Raises USD 7.9 Million In Venture Financing 19

Partnerships 20

RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 20

Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 21

ABL Enters into Contract Manufacturing Agreement with RegenxBio 22

Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 23

Licensing Agreements 24

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 24

Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 25

Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 26

AveXis Enters into Licensing Agreement with Regenxbio 27

RegenxBio Exercises its Option Agreement with Voyager Therapeutics 29

Biogen Enters into Licensing Agreement with RegenxBio 30

Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 31

Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 32

ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 34

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 35

Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 36

ReGenx Enters Into Licensing Agreement With AAVLife 38

AveXis Amends Licensing Agreement With ReGenX Biosciences 39

ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 40

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 41

Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 42

Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 43

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 44

Equity Offering 45

RegenxBio Raises USD201.8 Million in Public Offering of Shares 45

RegenxBio Prices Public Offering of Shares for USD75.9 Million 47

RegenxBio Raises USD159.4 Million in IPO 49

Acquisition 51

RegenxBio to Acquire Dimension Therapeutics 51

RegenxBio Inc-Key Competitors 53

RegenxBio Inc-Key Employees 54

RegenxBio Inc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 56

Strategy And Business Planning 56

May 15, 2018: REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation 56

Aug 09, 2017: The Silverstein Foundation, REGENXBIO, and OrbiMed Launch Prevail Therapeutics 57

Financial Announcements 58

Nov 07, 2018: REGENXBIO reports third quarter 2018 financial and operating results and announces initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II 58

May 08, 2018: REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights 61

Mar 06, 2018: REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights 63

Nov 08, 2017: REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights 65

Aug 08, 2017: REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 67

May 09, 2017: REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights 69

Mar 07, 2017: REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights 71

Jan 06, 2017: REGENXBIO Provides Year-End 2016 Corporate Update 73

Corporate Communications 75

May 29, 2018: REGENXBIO Names Alexandra Glucksmann As Board Director 75

Mar 28, 2017: REGENXBIO Enhances and Expands Scientific Leadership 76

Product News 77

Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting 77

Clinical Trials 81

Feb 08, 2018: REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 81

Sep 20, 2017: REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 82

Aug 11, 2017: REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists 83

Other Significant Developments 84

Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting 84

Jan 04, 2018: REGENXBIO Provides Year-End 2017 Corporate Update 88

Appendix 91

Methodology 91

About GlobalData 91

Contact Us 91

Disclaimer 91

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

RegenxBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

RegenxBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

REGENXBIO Raises USD70.5 Million in Series D Financing 13

REGENXBIO Raises USD30 Million in Series C Financing 16

REGENXBIO Raises USD7.9 Million in Venture Financing 18

ReGenX Biosciences Raises USD 7.9 Million In Venture Financing 19

RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 20

Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 21

ABL Enters into Contract Manufacturing Agreement with RegenxBio 22

Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 23

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 24

Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 25

Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 26

AveXis Enters into Licensing Agreement with Regenxbio 27

RegenxBio Exercises its Option Agreement with Voyager Therapeutics 29

Biogen Enters into Licensing Agreement with RegenxBio 30

Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 31

Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 32

ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 34

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 35

Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 36

ReGenx Enters Into Licensing Agreement With AAVLife 38

AveXis Amends Licensing Agreement With ReGenX Biosciences 39

ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 40

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 41

Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 42

Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 43

ReGenX Biosciences Enters Into Licensing Agreement With Esteve 44

RegenxBio Raises USD201.8 Million in Public Offering of Shares 45

RegenxBio Prices Public Offering of Shares for USD75.9 Million 47

RegenxBio Raises USD159.4 Million in IPO 49

RegenxBio to Acquire Dimension Therapeutics 51

RegenxBio Inc, Key Competitors 53

RegenxBio Inc, Key Employees 54

RegenxBio Inc, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

RegenxBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person